These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 709897)
21. DDAVP in the treatment of central diabetes insipidus. Robinson AG N Engl J Med; 1976 Mar; 294(10):507-11. PubMed ID: 1250255 [TBL] [Abstract][Full Text] [Related]
22. Familial cranial diabetes insipidus: a report of five families. Genetic, diagnostic and therapeutic aspects. Pedersen EB; Lamm LU; Albertsen K; Madsen M; Bruun-Petersen G; Henningsen K; Friedrich U; Magnusson K Q J Med; 1985 Dec; 57(224):883-96. PubMed ID: 4095258 [TBL] [Abstract][Full Text] [Related]
23. Tritiation of vasopressin analogues and their metabolic fate after intravenous injection in the rat. Janáky T; László FA; Morgat JL Acta Med Hung; 1984; 41(1):43-54. PubMed ID: 6739223 [TBL] [Abstract][Full Text] [Related]
24. Plasma concentrations of 1-deamino-8-D-arginine vasopressin after intragastric administration in the rat. Lundin S; Melin P; Vilhardt H Acta Endocrinol (Copenh); 1985 Feb; 108(2):179-83. PubMed ID: 3969814 [TBL] [Abstract][Full Text] [Related]
25. Effects of lysine-vasopressin and 1-deamino-8-D-arginine-vasopressin on memory in healthy individuals and diabetes insipidus patients. Laczi F; Valkusz Z; Lászlo FA; Wagner A; Járdánházy T; Szász A; Szilárd J; Telegdy G Psychoneuroendocrinology; 1982; 7(2-3):185-93. PubMed ID: 7178372 [TBL] [Abstract][Full Text] [Related]
26. Desmopressin. Richardson DW; Robinson AG Ann Intern Med; 1985 Aug; 103(2):228-39. PubMed ID: 3893256 [TBL] [Abstract][Full Text] [Related]
27. Impermeability of the blood-cerebrospinal fluid barrier to 1-deamino-8-D-arginine-vasopressin (DDAVP) in patients with acquired, communicating hydrocephalus. Sørensen PS; Vilhardt H; Gjerris F; Warberg J Eur J Clin Invest; 1984 Dec; 14(6):435-9. PubMed ID: 6441719 [TBL] [Abstract][Full Text] [Related]
28. [DDAVP in the treatment of acute neurosurgical diabetes insipidus]. Zancaner F; Griner A; Galante E Minerva Med; 1984 Apr; 75(18):1063-7. PubMed ID: 6728257 [TBL] [Abstract][Full Text] [Related]
29. [Experiences with the intranasal and parenteral use of 1-desamino-8-D-arginine vasopressin (DDAVP)--effect of one time parenteral and intranasal applications]. Tuschy U; Meinhold J; Szeszat S Z Gesamte Inn Med; 1983 Aug; 38(16):450-2. PubMed ID: 6636913 [TBL] [Abstract][Full Text] [Related]
30. Ten-year experience with DDAVP in treatment of diabetes insipidus. Marek J; Loutocký A; Pacovský V; Zaoral M Endokrinologie; 1978 May; 72(2):188-94. PubMed ID: 738214 [TBL] [Abstract][Full Text] [Related]
31. Effects of water deprivation and deamino [8-D-arginine] vasopressin on [14C]2-deoxyglucose uptake by the hypothalamo-hypophysial system in mice with hereditary nephrogenic diabetes insipidus. Sutherland RC; Fink G; Morris JF Brain Res; 1985 Aug; 340(2):297-303. PubMed ID: 4027654 [TBL] [Abstract][Full Text] [Related]
32. Control of sodium excretion in patients with cranial diabetes insipidus maintained on desamino-[8-D-arginine]vasopressin. Sutters M; Brace C; Hatfield E; Whitehurst A; Lightman SL; Peart WS Clin Sci (Lond); 1993 Nov; 85(5):599-606. PubMed ID: 8287649 [TBL] [Abstract][Full Text] [Related]
33. Epinephrine and dDAVP administration in patients with congenital nephrogenic diabetes insipidus. Evidence for a pre-cyclic AMP V2 receptor defective mechanism. Bichet DG; Razi M; Arthus MF; Lonergan M; Tittley P; Smiley RK; Rock G; Hirsch DJ Kidney Int; 1989 Nov; 36(5):859-66. PubMed ID: 2559238 [TBL] [Abstract][Full Text] [Related]
34. Effects of thirsting on biological half-life and organ distribution of 3H-dDAVP in rat. Janáky T; László FA; Baláspiri L; Morgat JL Horm Metab Res; 1982 Jul; 14(7):385-6. PubMed ID: 7118063 [No Abstract] [Full Text] [Related]
35. [Treatment of ADP responsive diabetes insipidus in children with DDAVP (1-desamino-8-D-arginine-vasopressin)]. Limal JM; Mugner E; Czernichow P Arch Fr Pediatr; 1977 Dec; 34(10):965-72. PubMed ID: 610662 [TBL] [Abstract][Full Text] [Related]
36. Antidiuretic and PGE2 responses to AVP and dDAVP in subjects with central and nephrogenic diabetes insipidus. Moses AM; Scheinman SJ; Schroeder ET Am J Physiol; 1985 Mar; 248(3 Pt 2):F354-9. PubMed ID: 3856399 [TBL] [Abstract][Full Text] [Related]
37. The effects of water deprivation and water loading during treatment with 1-deamino-8-D-arginine vasopressin in central diabetes insipidus in childhood. Becker DJ; Foley TP Acta Endocrinol (Copenh); 1981 Jul; 97(3):358-60. PubMed ID: 7257701 [TBL] [Abstract][Full Text] [Related]
39. [Long-term treatment of central diabetes insipidus with oral DDAVP]. Carraro A; Fano M; Cuttica M; Bernareggi V; Giusti M; Giordano G Minerva Endocrinol; 1992; 17(4):189-93. PubMed ID: 1308923 [TBL] [Abstract][Full Text] [Related]
40. Shortened duration of action of 1-deamino-8-D-arginine vasopressin (DDAVP) in patients with diabetes insipidus requiring high doses of peroral antidiuretic drugs. Radó JP; Marosi J; Fischer J J Clin Pharmacol; 1976 Oct; 16(10 Pt 1):518-24. PubMed ID: 789414 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]